Obstetrics, gynaecology & urinary-tract disorder - commissioning policies
Avanafil for erectile dysfunction
Botulinum Toxin for urinary incontinence due to detrusor overactivity
Cryopreservation to preserve fertility
Dapoxetine for Premature Ejaculation
Referral for the Surgical Management of Heavy Menstrual Bleeding
Jaydess Levonorgestrel 13.5mg intrauterine system (IUS) for contraception
Tadalafil 5mg tablets (Cialis®) for lower urinary tract symptoms (LUTS) in adult men
Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here
The CCGs’ position on the implementation of policies affecting patient referral can be found here
Safety update: Esmya® (ulipristal acetate)
Ulipristal acetate 5mg tablets (Esmya®) for intermittent treatment of uterine fibroids
Please note in February 2018 the MHRA introduced new temporary safety measures for Esmya® (ulipristal acetate) following reports of serious liver injury in women using the medicine for uterine fibroids.
This advises: do not initiate treatment in new users or those between treatment courses; monitor liver function in current and recent users.
For more information please visit the respective Joint Formulary for South and West Devon and North and East Devon.
Some commissioning policies approved by the previous commissioning organisations have not been reviewed and updated yet. However they are still applicable for the local population and can be accessed here